Bio Key International INC

BIO-key International, Inc. has appointed M&K CPAS, PLLC as its new independent registered public accounting firm, while dismissing Bush & Associates CPA LLC.

BIO-key International announced its common stock will resume trading on the Nasdaq Capital Market on July 8, 2026, after regaining compliance with listing standards.

BIO-key International has received a notice of non-compliance from Nasdaq due to the delayed filing of its Form 10-Q for the period ended March 31, 2026.

BIO-key International reports a 34% revenue increase in Q1 2026, with significant improvements in net loss, and anticipates profitability in Q2 2026 driven by a projected 65% revenue surge.

BIO-key International's common stock will be suspended from Nasdaq trading effective May 12, 2026, due to bid price and late filing issues, with trading to commence on OTC Markets the following day.

BIO-key International stockholders have authorized the Board of Directors to implement a reverse stock split at a ratio between 1-for-2 and 1-for-10.

BIO-key International reported a significant increase in cash and working capital for Q3 2025, driven by financing activities, despite continued operating losses and a decline in overall revenue.

BIO-key International, Inc. reported a reduced net loss and increased cash, but continues to face substantial doubt about its ability to continue as a going concern.

BIO-key International's Q1 2025 revenue decreased due to a shift in sales strategy, but warrant exercises boosted cash reserves.

Bio-Key International's Q3 2024 results show increased revenue in license fees and hardware sales, but the company continues to face net losses and going concern challenges.

BIO-key International's Q2 2024 results show a significant revenue decrease compared to the previous year, alongside a new secured promissory note to bolster working capital.

BIO-key International's Q1 2024 results show a slight decrease in overall revenue, but a significant improvement in gross profit, alongside ongoing efforts to address internal control weaknesses.

BIO-key International reports a net loss of $7.16 million for 2025 amid ongoing liquidity challenges and Nasdaq delisting.

BIO-key International's 10-K filing reveals a strategic shift towards higher-margin license sales and cost reductions, despite a revenue decrease.

BIO-key International has filed an amendment to its annual report to correct a typographical error in the date of the auditor's report, with no other changes to the financial statements.

BIO-key International restated its 2023 quarterly financials due to revenue recognition errors and internal control weaknesses, while also reporting a 10% increase in annual revenue.

James David Sullivan, Chief Legal Officer and SVP Strategy & Compliance at BIO-key International, acquired 250 shares of common stock under an employee stock purchase plan.

Michael DePasquale, CEO of Bio-Key International, acquired 250 shares of common stock through an employee stock purchase plan.

BIO-key International's Chief Technology Officer, Mira LaCous, acquired shares through an employee stock purchase plan.

BIO-key International's Chief Technology Officer, Mira Lacous, acquired 2,500 shares of common stock at $0.46 per share through an employee stock purchase plan.

BIO-key International's Chief Legal Officer, James D. Sullivan, acquired 2,500 shares of common stock at $0.46 per share through an employee stock purchase plan.

BIO-key International CEO Michael W. DePasquale acquired 2,500 shares of common stock at $0.46 per share through the company's Employee Stock Purchase Plan.

BIO-key International announces its 2026 Annual Meeting of Stockholders, scheduled for September 3, 2026, to elect directors, ratify auditors, and vote on executive compensation.

BIO-key International, Inc. is calling a special meeting for stockholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

BIO-key International, Inc. has filed its definitive proxy statement for its 2025 Annual Meeting of Stockholders, seeking approval for the election of five directors, ratification of its independent auditor, an advisory vote on executive compensation, and amendments to its 2023 Stock Incentive Plan and 2021 Employee Stock Purchase Plan.

BIO-key International will hold its 2024 Annual Meeting of Stockholders on August 22, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

BIO-key International, Inc. filed an S-1 registration statement for the resale of up to 6.18 million common shares by a selling stockholder, while also detailing recent warrant exercises that generated over $9 million for the company.

BIO-key International is registering for the resale of up to 3,091,668 shares of its common stock by a selling stockholder, with the company not receiving any proceeds from the sale.

BIO-key International is registering the resale of up to 2,061,112 shares of its common stock by a selling stockholder, with the company not receiving any proceeds from the sale.

BIO-key International is registering the resale of up to 436,509 shares of its common stock by a selling stockholder, Dillon Hill Investment Company LLC, with the company not receiving any proceeds from the sale.

Armistice Capital and Steven Boyd have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in BIO-KEY International Inc. as of June 30, 2025.

Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, has filed an amended Schedule 13G disclosing a 3.6% beneficial ownership stake in BIO KEY INTERNATIONAL INC.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% passive ownership stake in BIO-key International Inc. through a Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in BIO-key International Inc.'s common stock as of December 31, 2024.

Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, has disclosed a beneficial ownership of 9.1% in BIO-key International Inc.'s common stock.